The proapoptotic effect of formononetin in human osteosarcoma cells: Involvement of inactivation of ERK and Akt pathways

Cellular Physiology and Biochemistry

Volumn 34, Issue 3, 2014, Pages 637-645

  Liu, Yun ^a   He, Jinjie ^b   Chen, Xiaoming ^a   Li, Jian ^a   Shen, Maorong ^b   Yu, Wenjun ^b   Yang, Yuan ^b   Xiao, Zengming ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

^b Orthopaedic Hospital of Guangxi   (China)

Author keywords

Apoptosis; Calycosin; Formononetin; MAPK; Osteosarcoma; PI3K Akt

Indexed keywords

ANTINEOPLASTIC AGENT; CALYCOSIN; CASPASE 3; FORMONONETIN; ISOFLAVONE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; UNCLASSIFIED DRUG; 7,3'-DIHYDROXY-4'-METHOXYISOFLAVONE;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; ASTRAGALUS PLANT; CANCER INHIBITION; CELL PROLIFERATION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; MTT ASSAY; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; U2OS CELL LINE; UPREGULATION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; ISOFLAVONES; OSTEOSARCOMA; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 84906589043     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000363029     Document Type: Article

References (34)

1. Zhu Y, Zhou J, Ji Y, Yu B: Elevated expression of AKT2 correlates with disease severity and poor prognosis in human osteosarcoma. Mol Med Rep 2014;10:737-742.
2. Arndt CA, Rose PS, Folpe AL, Laack NN: Common musculoskeletal tumors of childhood and adolescence. Mayo Clin Proc 2012;87:475-487.
3. Robert G, Chappé C, Taque S, Bruneau B, Gandemer V: Hearing loss during osteosarcoma chemotherapy: when acute ifosfamide toxicity revealed unnoticed methotrexate. J Pediatr Hematol Oncol 2014;36:e100-102.
4. Manolagas SC, O'Brien CA, Almeida M: The role of estrogen and androgen receptors in bone health and disease. Nat Rev Endocrinol 2013;9:699-712.
5. May FE: Novel drugs that target the estrogen-related receptor alpha: their therapeutic potential in breast cancer. Cancer Manag Res 2014;6:225-252.
6. Svoboda M, Hamilton G, Thalhammer T: Steroid hormone metabolizing enzymes in benign and malignant human bone tumors. Expert Opin Drug Metab Toxicol 2010;6:427-437.
7. Rietjens IM, Sotoca AM, Vervoort J, Louisse J: Mechanisms underlying the dualistic mode of action of major soy isoflavones in relation to cell proliferation and cancer risks. Mol Nutr Food Res 2013;57:100-113.
8. Lin AH, Li RW, Ho EY, Leung GP, Leung SW, Vanhoutte PM, Man RY: Differential ligand binding affinities of human estrogen receptor-α isoforms. PLoS One 2013;8:e63199.
9. Yang Y, Chin A, Zhang L, Lu J, Wong RW: The role of traditional Chinese medicines in osteogenesis and angiogenesis. Phytother Res 2014;28:1-8.
10. Zhang X, Bi L, Ye Y, Chen J: Formononetin induces apoptosis in PC-3 prostate cancer cells through enhancing the Bax/Bcl-2 ratios and regulating the p38/Akt pathway. Nutr Cancer 2014;66:656-661.
11. Chen J, Zhao X, Ye Y, Wang Y, Tian J: Estrogen receptor beta-mediated proliferative inhibition and apoptosis in human breast cancer by calycosin and formononetin. Cell Physiol Biochem 2013;32:1790-1797.
12. Huang WJ, Bi LY, Li ZZ, Zhang X, Ye Y: Formononetin induces the mitochondrial apoptosis pathway in prostate cancer cells via downregulation of the IGF-1/IGF-1R signaling pathway. Pharm Biol 2014;52:466-470.
13. Botter SM, Neri D, Fuchs B: Recent advances in osteosarcoma. Curr Opin Pharmacol 2014;16C:15-23.
14. Zhang C, Peng J, Wu S, Jin Y, Xia F, Wang C, Liu K, Sun H, Liu M: Dioscin promotes osteoblastic proliferation and differentiation via Lrp5 and ER pathway in mouse and human osteoblast-like cell lines. J Biomed Sci 2014;21:30.
15. Lee CH, Huang YL, Liao JF, Chiou WF: Ugonin K-stimulated osteogenesis involves estrogen receptordependent activation of non-classical Src signaling pathway and classical pathway. Eur J Pharmacol 2012;676:26-33.
16. Hwang KA, Park MA, Kang NH, Yi BR, Hyun SH, Jeung EB, Choi KC: Anticancer effect of genistein on BG-1 ovarian cancer growth induced by 17 β-estradiol or bisphenol A via the suppression of the crosstalk between estrogen receptor α and insulin-like growth factor-1 receptor signaling pathways. Toxicol Appl Pharmacol 2013;272:637-646.
17. Thelen P, Wuttke W, Seidlová-Wuttke D: Phytoestrogens selective for the estrogen receptor beta exert antiandrogenic effects in castration resistant prostate cancer. J Steroid Biochem Mol Biol 2014;139:290-293.
18. Collins-Burow BM, Antoon JW, Frigo DE, Elliott S, Weldon CB, Boue SM, Beckman BS, Curiel TJ, Alam J, McLachlan JA, Burow ME: Antiestrogenic activity of flavonoid phytochemicals mediated via the c-Jun N-terminal protein kinase pathway. Cell-type specific regulation of estrogen receptor alpha. J Steroid Biochem Mol Biol 2012;132:186-193.
19. Nakamura A, Aizawa J, Sakayama K, Kidani T, Takata T, Norimatsu Y, Miura H, Masuno H: Genistein inhibits cell invasion and motility by inducing cell differentiation in murine osteosarcoma cell line LM8. BMC Cell Biol 2012;13:24.
20. Chen J, Sun L: Formononetin-induced apoptosis by activation of Ras/p38 mitogen-activated protein kinase in estrogen receptor-positive human breast cancer cells. Horm Metab Res 2012;44:943-948.
21. Tian J, Duan YX, Bei CY, Chen J: Calycosin induces apoptosis by upregulation of RASD1 in human breast cancer cells MCF-7. Horm Metab Res 2013;45:593-598.
22. Hensley P, Mishra M, Kyprianou N: Targeting caspases in cancer therapeutics. Biol Chem 2013;394: 831-843.
23. Fiandalo MV, Kyprianou N: Caspase control: protagonists of cancer cell apoptosis. Exp Oncol 2012;34:165-175.
24. Mansoor TA, Ramalho RM, Luo X, Ramalhete C, Rodrigues CM, Ferreira MJ: Isoflavones as apoptosis inducers in human hepatoma HuH-7 cells. Phytother Res 2011;25:1819-1824.
25. Diab S, Kumarasiri M, Yu M, Teo T, Proud C, Milne R, Wang S: MAP kinase-interacting kinases-emerging targets against cancer. Chem Biol 2014;21:441-452.
26. Dupont J, Reverchon M, Cloix L, Froment P, Ramé C: Involvement of adipokines, AMPK, PI3K and the PPAR signaling pathways in ovarian follicle development and cancer. Int J Dev Biol 2012;56:959-967.
27. Shin DY, Kim GY, Hwang HJ, Kim WJ, Choi YH: Diallyl trisulfide-induced apoptosis of bladder cancer cells is caspase-dependent and regulated by PI3K/Akt and JNK pathways. Environ Toxicol Pharmacol 2014;37:74-83.
28. Rahmani M, Aust MM, Attkisson E, Williams DC Jr, Ferreira-Gonzalez A, Grant S: Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3-and Bim-dependent mechanism. Cancer Res 2013;73:1340-1351.
29. Monian P, Jiang X: Clearing the final hurdles to mitochondrial apoptosis: regulation post cytochrome C release. Exp Oncol 2012;34:185-191.
30. Martinou JC, Youle RJ: Mitochondria in apoptosis: Bcl-2 family members and mitochondrial dynamics. Dev Cell 2011;21:92-101.
31. Soriano ME, Scorrano L: The interplay between BCL-2 family proteins and mitochondrial morphology in the regulation of apoptosis. Adv Exp Med Biol 2010;687:97-114.
32. Park JS, Kwon JK, Kim HR, Kim HJ, Kim BS, Jung JY: Farnesol induces apoptosis of DU145 prostate cancer cells through the PI3K/Akt and MAPK pathways. Int J Mol Med 2014;33:1169-1176.
33. Vitagliano O, Addeo R, D'Angelo V, Indolfi C, Indolfi P, Casale F: The Bcl-2/Bax and Ras/Raf/MEK/ERK signaling pathways: implications in pediatric leukemia pathogenesis and new prospects for therapeutic approaches. Expert Rev Hematol 2013;6:587-597.
34. Miwa S, Sugimoto N, Yamamoto N, Shirai T, Nishida H, Hayashi K, Kimura H, Takeuchi A, Igarashi K, Yachie A, Tsuchiya H: Caffeine induces apoptosis of osteosarcoma cells by inhibiting AKT/mTOR/S6K, NF-κB and MAPK pathways. Anticancer Res 2012;32:3643-3649.